1. Home
  2. EAF vs CADL Comparison

EAF vs CADL Comparison

Compare EAF & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GrafTech International Ltd.

EAF

GrafTech International Ltd.

HOLD

Current Price

$7.73

Market Cap

429.4M

Sector

Energy

ML Signal

HOLD

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$4.90

Market Cap

357.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EAF
CADL
Founded
1886
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
429.4M
357.4M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
EAF
CADL
Price
$7.73
$4.90
Analyst Decision
Hold
Strong Buy
Analyst Count
4
8
Target Price
$11.75
$19.00
AVG Volume (30 Days)
215.8K
1.1M
Earning Date
05-01-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.62
EPS
N/A
N/A
Revenue
$504,134,000.00
$125,000.00
Revenue This Year
$4.25
N/A
Revenue Next Year
$12.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$4.34
52 Week High
$20.32
$7.24

Technical Indicators

Market Signals
Indicator
EAF
CADL
Relative Strength Index (RSI) 59.18 47.36
Support Level $7.65 $4.57
Resistance Level $7.73 $5.25
Average True Range (ATR) 0.64 0.22
MACD 0.28 0.02
Stochastic Oscillator 87.21 60.13

Price Performance

Historical Comparison
EAF
CADL

About EAF GrafTech International Ltd.

GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: